These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J; N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696 [TBL] [Abstract][Full Text] [Related]
8. [Therapy with ACE inhibitors in chronic heart failure and limited kidney function]. Osterziel KJ; Nagel F; Dietz R Z Kardiol; 1994; 83 Suppl 4():81-7. PubMed ID: 7856286 [TBL] [Abstract][Full Text] [Related]
9. The effect of infrarenal aortic reconstruction on glomerular filtration rate and effective renal plasma flow. Awad RW; Barham WJ; Taylor DN; Woodward DA; Bullen BR Eur J Vasc Surg; 1992 Jul; 6(4):362-7. PubMed ID: 1499737 [TBL] [Abstract][Full Text] [Related]
10. Are the renal haemodynamic and natriuretic effects of calcium antagonists and angiotensin converting inhibitors additive? Natov S; Hannedouche T; Schmitt F; Ikeni A; Déchaux M; Kirkisseli S; Lacour B; Grünfeld JP J Hypertens Suppl; 1991 Dec; 9(6):S392-3. PubMed ID: 1819003 [No Abstract] [Full Text] [Related]
11. The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure. Cleland JG; Gillen G; Dargie HJ Eur Heart J; 1988 Feb; 9(2):132-41. PubMed ID: 2832173 [TBL] [Abstract][Full Text] [Related]
12. The angiotensin converting enzyme inhibitor enalapril and its effects on renal function. de Zeeuw D; Navis GJ; Donker AJ; de Jong PE J Hypertens Suppl; 1983 Oct; 1(1):93-7. PubMed ID: 6100614 [TBL] [Abstract][Full Text] [Related]
13. Divergent effects of ACE-inhibition and calcium channel blockade on NO-activity in systemic and renal circulation in essential hypertension. Dijkhorst-Oei LT; Beutler JJ; Stroes ES; Koomans HA; Rabelink TJ Cardiovasc Res; 1998 Nov; 40(2):402-9. PubMed ID: 9893735 [TBL] [Abstract][Full Text] [Related]
14. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Cleland JG; Dargie HJ; Ball SG; Gillen G; Hodsman GP; Morton JJ; East BW; Robertson I; Ford I; Robertson JI Br Heart J; 1985 Sep; 54(3):305-12. PubMed ID: 2994698 [TBL] [Abstract][Full Text] [Related]
15. Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Mosconi L; Ruggenenti P; Perna A; Mecca G; Remuzzi G Kidney Int Suppl; 1996 Jun; 55():S91-3. PubMed ID: 8743521 [TBL] [Abstract][Full Text] [Related]
16. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753 [TBL] [Abstract][Full Text] [Related]
17. Renal haemodynamics and function in weanling rats treated with enalapril from birth. Guron G Clin Exp Pharmacol Physiol; 2005 Oct; 32(10):865-70. PubMed ID: 16173949 [TBL] [Abstract][Full Text] [Related]
18. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. Falk RJ; Scheinman J; Phillips G; Orringer E; Johnson A; Jennette JC N Engl J Med; 1992 Apr; 326(14):910-5. PubMed ID: 1542341 [TBL] [Abstract][Full Text] [Related]
19. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283 [TBL] [Abstract][Full Text] [Related]
20. Norepinephrine-induced blood pressure rise and renal vasoconstriction are not attenuated by enalapril treatment in microalbuminuric IDDM. Hoogenberg K; Navis G; Dullaart RP Nephrol Dial Transplant; 1998 Mar; 13(3):640-5. PubMed ID: 9550640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]